Pharmacokinetic and pharmacodynamic analyses, based on dopamine D 2-receptor occupancy of bromocriptine, of bromocriptine-induced contralateral rotations in unilaterally 6-OHDA-lesioned rats

Synapse

Volumn 50, Issue 2, 2003, Pages 110-116

  Atsumi, Masako ^a   Kawakami, Junichi ^b   Sugiyama, Erika ^a   Kotaki, Hajime ^c   Sawada, Yasufumi ^d   Sato, Hitoshi ^e   Yamada, Yasuhiko ^f   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY   (Japan)

^f TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Bromocriptine; Dopamine D2 receptor occupancy; PK PD analyses

Indexed keywords

APOMORPHINE; BROMOCRIPTINE MESILATE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ERGOCRYPTINE; OXIDOPAMINE; RACLOPRIDE; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

ANIMALS; BROMOCRIPTINE; DENERVATION; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NEOSTRIATUM; NEURAL PATHWAYS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, DOPAMINE D2; ROTATION; SUBSTANTIA NIGRA;

EID: 0141518338     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10248     Document Type: Article

References (31)

1. 2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys. Jpn J Pharmacol 67:117-124.
2. 1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease. J Pharmacol Exp Ther 281:454-459.
3. Bodagh IY, Robertson DR. 1994. A risk-benefit assessment of drugs used in the management of Parkinson's disease. Drug Saf 11:94-103.
4. Borlongan CV, Sanberg PR. 1995. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 15:5372-5378.
5. Clemens JA, Okimura T, Smalstig EB. 1993. Dopamine agonist activities of pergolide, its metabolites, and bromocriptine as measured by prolactin inhibition, compulsive turning, and stereotypic behavior. Arzneimittelforschung 43:281-286.
6. Corrodi H, Fuxe K, Hokfelt T, Lidbrink P, Ungerstedt U. 1973. Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 25:409-412.
7. Duvoisin RC, Heikkila RE, Manzino L. 1982. Pergolide-induced circling in rats with 6-hydroxydopamine lesions in the nigrostriatal pathway. Neurology 32:1387-1391.
8. 2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat-an autoradiographic study. Brain Res 640:185-194.
9. 1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res 514:93-102.
10. 2, and muscarinic acetylcholine receptor occupancies. Drug Metab Dispos 25:675-684.
11. 3H]spiroperidol binding and rotational behavior in unilaterally 6-hydroxydopamine-lesioned rats. Brain Res 211:285-292.
12. 2 receptor sites. Eur J Pharmacol 98:165-176.
13. Ito K, Sawada Y, Sugiyama Y, Hanano M, Iga T. 1991. Kinetic evaluation for measurement of in vivo receptor occupancy by psychotropic drug in brain: implication for human studies. Chem Pharm Bull 39:1813-1819.
14. Johnson AM, Loew DM, Vigouret JM. 1976. Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA. Br J Pharmacol 56:59-68.
15. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34:2251-2259.
16. Koller WC, Weiner WJ, Diamond BI, Nausieda PA, Klawans HL. 1980. The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent. Neuropharmacology 19:831-837.
17. Matsuda H, Akechi Y, Shimada Y, Terasawa K, Watanabe H. 1995. Relationship of the ipsilateral rotation in night period and striatal dopamine content reduction in unilateral nigrostriatal 6-OHDA lesioned rats. Brain Res 686:111-114.
18. Mendez JS, Finn BW. 1975. Use of 6-hydroxydopa: nine to create lesions in catecholamine neurons in rats. J Neurosurg 42:166-173.
19. Montastruc JL, Rascol O, Senard JM. 1993. Current status of dopamine agonists in Parkinson's disease management. Drugs 46:384-393.
20. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artaeda J, Lera G, Rodriguez ME, Martinez-Lage JM. 1989. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39(Suppl 2):11-19.
21. Ogawa N, Mizukawa K, Haba K, Sato H. 1990. Neurot ransmitter and receptor alterations in the rat persistent dyskinesia model induced by iminodipropionitrile. Eur Neurol 30(Suppl 1):31-40.
22. Phelan DG, Greig NH, Rapoport SI, Soncrant TT. 1990. High-performance liquid chromatographic assay of bromocriptir e in rat plasma and brain. J Chromatogr A 533:264-270.
23. Schran HF, Tse FL, Bhuta SI. 1985. Pharmacokinetics and pharmacodynamics of bromocriptine in the rat. Biopharm Drug Dispos 6:301-311.
24. Silverman PB. 1993. On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat. Eur J Pharmacol 242:31-36.
25. Stern MB. 1997. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology 49(Suppl 1):S2-9.
26. Thornburg JE, Moore KE. 1975. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice. J Pharmacol Exp Ther 192:42-49.
27. Ungerstedt U. 1971a. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 367:49-68.
28. Ungerstedt U. 1971b. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93.
29. Wachtel H. 1991. Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans. J Neural Transm 3:151-201.
30. Wong DT, Threlkeld PG, Bymaster FP. 1993. Dopamine receptor affinities in vitro and neurochemical effects in vivo of pergolide and its metabolites. Arzneimittelforschung 43:409-412.
31. Zigmond MJ, Stricker EM. 1980. Supersensitivity after intraventricular 6-hydroxydopamine: relation to dopamine depletion. Experientia 36:436-438.